$17.63
-0.01-0.06%
À la fermeture: -
$17.59
-0.04-0.23%
Après les heures de négociation: Nov 7, 7:37 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Sarepta Therapeutics Inc a un objectif de cours consensuel de $26 basé sur les évaluations de 28 analystes. Le plus élevé est $81, publié par Cantor Fitzgerald le mai 7, 2025. Le plus bas est $5, publié par HC Wainwright & Co. le août 25, 2025. Les 3 évaluations d’analystes les plus récentes ont été publiées par Barclays, Wells Fargo et Guggenheim le novembre 5, 2025, respectivement. Avec un objectif de cours moyen de $28 entre Barclays, Wells Fargo et Guggenheim, il existe une variation implicite de 59.18% upside pour Sarepta Therapeutics Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Barclays
Wells Fargo
Guggenheim
Mizuho
Baird
1calculé à partir des notes des analystes
Notes d'analystes pour Sarepta Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/05/2025 | 13.7% | Barclays | $22 → $20 | Maintains | Equal-Weight | |||
11/05/2025 | 155.83% | Wells Fargo | $50 → $45 | Maintains | Overweight | |||
11/05/2025 | 8.02% | Guggenheim | $22 → $19 | Maintains | Buy | |||
11/05/2025 | 47.81% | Mizuho | $19 → $26 | Upgrade | Neutral → Outperform | |||
11/04/2025 | -14.72% | Baird | $21 → $15 | Maintains | Neutral | |||
10/30/2025 | -9.04% | Piper Sandler | $15 → $16 | Maintains | Neutral | |||
09/22/2025 | 184.25% | BMO Capital | $50 → $50 | Upgrade | Market Perform → Outperform | |||
09/15/2025 | 25.07% | Guggenheim | $22 → $22 | Reiterates | Buy → Buy | |||
09/09/2025 | -14.72% | Leerink Partners | $12 → $15 | Maintains | Market Perform | |||
08/25/2025 | -71.57% | HC Wainwright & Co. | $5 → $5 | Reiterates | Sell → Sell | |||
08/21/2025 | -9.04% | B of A Securities | $17 → $16 | Maintains | Underperform | |||
08/20/2025 | -3.35% | B of A Securities | $10 → $17 | Maintains | Underperform | |||
08/15/2025 | -31.78% | Deutsche Bank | $6 → $12 | Maintains | Sell | |||
08/07/2025 | 8.02% | Goldman Sachs | $10 → $19 | Maintains | Neutral | |||
08/07/2025 | 184.25% | Wells Fargo | $48 → $50 | Maintains | Overweight | |||
07/30/2025 | 25.07% | Barclays | $10 → $22 | Upgrade | Underweight → Equal-Weight | |||
07/29/2025 | 25.07% | Barclays | $10 → $22 | Upgrade | Underweight → Equal-Weight | |||
07/29/2025 | -14.72% | Piper Sandler | $11 → $15 | Maintains | Neutral | |||
07/29/2025 | -26.09% | Bernstein | → $13 | Initiates | → Market Perform | |||
07/29/2025 | 184.25% | BMO Capital | $25 → $50 | Maintains | Market Perform | |||
07/29/2025 | 110.35% | Oppenheimer | $30 → $37 | Upgrade | Perform → Outperform | |||
07/29/2025 | 13.7% | Morgan Stanley | $15 → $20 | Maintains | Equal-Weight | |||
07/29/2025 | 36.44% | JP Morgan | → $24 | Upgrade | Underweight → Neutral | |||
07/29/2025 | — | Needham | — | Reiterates | Underperform → Underperform | |||
07/28/2025 | — | Needham | — | Reiterates | Underperform → Underperform | |||
07/27/2025 | -43.15% | Barclays | $18 → $10 | Downgrade | Equal-Weight → Underweight | |||
07/25/2025 | -65.89% | Deutsche Bank | $9 → $6 | Maintains | Sell | |||
07/25/2025 | — | JP Morgan | — | Downgrade | Neutral → Underweight | |||
07/24/2025 | 98.98% | Jefferies | $40 → $35 | Maintains | Buy | |||
07/24/2025 | 172.88% | Wells Fargo | $65 → $48 | Maintains | Overweight | |||
07/24/2025 | -60.2% | Citigroup | → $7 | Initiates | → Sell | |||
07/23/2025 | -43.15% | B of A Securities | $20 → $10 | Downgrade | Neutral → Underperform | |||
07/22/2025 | 42.13% | BMO Capital | $50 → $25 | Maintains | Market Perform | |||
07/22/2025 | -37.46% | Piper Sandler | $18 → $11 | Maintains | Neutral | |||
07/22/2025 | 2.33% | Barclays | $32 → $18 | Downgrade | Overweight → Equal-Weight | |||
07/22/2025 | — | Needham | — | Reiterates | Underperform → Underperform | |||
07/21/2025 | -48.83% | Deutsche Bank | $25 → $9 | Downgrade | Hold → Sell | |||
07/21/2025 | -31.78% | UBS | $45 → $12 | Downgrade | Buy → Neutral | |||
07/21/2025 | -20.41% | Mizuho | $40 → $14 | Downgrade | Outperform → Neutral | |||
07/21/2025 | 2.33% | Piper Sandler | $32 → $18 | Maintains | Neutral | |||
07/21/2025 | 184.25% | BMO Capital | $70 → $50 | Maintains | Market Perform | |||
07/21/2025 | -43.15% | Leerink Swann | $45 → $10 | Downgrade | Outperform → Market Perform | |||
07/21/2025 | 13.7% | JP Morgan | $28 → $20 | Maintains | Overweight | |||
07/21/2025 | — | Needham | — | Downgrade | Hold → Underperform | |||
07/18/2025 | 184.25% | Needham | $50 → $50 | Downgrade | Buy → Hold | |||
07/18/2025 | 13.7% | B of A Securities | $28 → $20 | Maintains | Neutral | |||
07/18/2025 | 133.09% | Oppenheimer | $45 → $41 | Maintains | Outperform | |||
07/17/2025 | 269.53% | Wells Fargo | $75 → $65 | Maintains | Overweight | |||
07/17/2025 | 81.92% | Barclays | $29 → $32 | Maintains | Overweight | |||
07/17/2025 | 30.76% | RBC Capital | $25 → $23 | Maintains | Sector Perform | |||
07/17/2025 | 98.98% | Baird | $30 → $35 | Maintains | Outperform | |||
07/17/2025 | 184.25% | Needham | $50 → $50 | Reiterates | Buy → Buy | |||
07/10/2025 | 59.18% | JP Morgan | $30 → $28 | Maintains | Overweight | |||
06/25/2025 | -43.15% | HC Wainwright & Co. | $40 → $10 | Downgrade | Neutral → Sell | |||
06/22/2025 | 70.55% | JP Morgan | $84 → $30 | Maintains | Overweight | |||
06/20/2025 | 155.83% | Oppenheimer | $123 → $45 | Maintains | Outperform | |||
06/20/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
06/18/2025 | 127.4% | Mizuho | $85 → $40 | Maintains | Outperform | |||
06/17/2025 | 42.13% | Deutsche Bank | $50 → $25 | Maintains | Hold | |||
06/17/2025 | 64.87% | Goldman Sachs | → $29 | Downgrade | Buy → Neutral | |||
06/17/2025 | 127.4% | Morgan Stanley | $113 → $40 | Downgrade | Overweight → Equal-Weight | |||
06/17/2025 | 70.55% | Baird | $60 → $30 | Maintains | Outperform | |||
06/17/2025 | 326.38% | Wells Fargo | $100 → $75 | Maintains | Overweight | |||
06/17/2025 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
06/17/2025 | 64.87% | Barclays | $89 → $29 | Maintains | Overweight | |||
06/16/2025 | 206.99% | Jefferies | $125 → $54 | Maintains | Buy | |||
06/16/2025 | 59.18% | B of A Securities | $76 → $28 | Downgrade | Buy → Neutral | |||
06/16/2025 | 297.95% | BMO Capital | $120 → $70 | Downgrade | Outperform → Market Perform | |||
06/16/2025 | 104.66% | Piper Sandler | $70 → $36 | Downgrade | Overweight → Neutral | |||
06/16/2025 | 184.25% | Needham | $125 → $50 | Maintains | Buy | |||
06/16/2025 | -43.15% | HC Wainwright & Co. | $40 → $10 | Downgrade | Neutral → Sell | |||
06/06/2025 | 354.8% | Scotiabank | $80 → $80 | Upgrade | Sector Perform → Sector Outperform | |||
05/22/2025 | 127.4% | HC Wainwright & Co. | $40 → $40 | Reiterates | Neutral → Neutral | |||
05/20/2025 | 377.54% | JP Morgan | $169 → $84 | Maintains | Overweight | |||
05/09/2025 | 383.23% | Mizuho | $179 → $85 | Maintains | Outperform | |||
05/08/2025 | 468.5% | Wells Fargo | $115 → $100 | Maintains | Overweight | |||
05/07/2025 | 241.1% | Baird | $193 → $60 | Maintains | Outperform | |||
05/07/2025 | 405.97% | Barclays | $209 → $89 | Maintains | Overweight | |||
05/07/2025 | 229.73% | RBC Capital | $87 → $58 | Maintains | Sector Perform | |||
05/07/2025 | 468.5% | Goldman Sachs | $178 → $100 | Maintains | Buy | |||
05/07/2025 | 457.13% | Guggenheim | $112 → $98 | Maintains | Buy | |||
05/07/2025 | 297.95% | Piper Sandler | $110 → $70 | Maintains | Overweight | |||
05/07/2025 | 599.26% | Oppenheimer | $184 → $123 | Maintains | Outperform | |||
05/07/2025 | 360.49% | Cantor Fitzgerald | $163 → $81 | Maintains | Overweight | |||
05/07/2025 | 127.4% | HC Wainwright & Co. | $75 → $40 | Maintains | Neutral | |||
05/07/2025 | 542.41% | Morgan Stanley | $182 → $113 | Maintains | Overweight | |||
05/07/2025 | 610.63% | Needham | $183 → $125 | Maintains | Buy | |||
04/21/2025 | 525.36% | Piper Sandler | $182 → $110 | Maintains | Overweight | |||
04/16/2025 | 326.38% | HC Wainwright & Co. | $75 → $75 | Reiterates | Neutral → Neutral | |||
04/11/2025 | 934.68% | Morgan Stanley | $196 → $182 | Maintains | Overweight | |||
04/11/2025 | 553.78% | Wells Fargo | → $115 | Initiates | → Overweight | |||
04/07/2025 | 326.38% | HC Wainwright & Co. | $75 → $75 | Reiterates | Neutral → Neutral | |||
04/04/2025 | 326.38% | HC Wainwright & Co. | $75 → $75 | Reiterates | Neutral → Neutral | |||
04/03/2025 | 940.36% | Needham | $202 → $183 | Maintains | Buy | |||
04/02/2025 | 326.38% | HC Wainwright & Co. | $75 → $75 | Upgrade | Sell → Neutral | |||
03/31/2025 | 394.6% | RBC Capital | $161 → $87 | Downgrade | Outperform → Sector Perform | |||
03/20/2025 | 354.8% | Scotiabank | $105 → $80 | Maintains | Sector Perform | |||
03/19/2025 | 826.66% | Cantor Fitzgerald | $163 → $163 | Reiterates | Overweight → Overweight | |||
03/19/2025 | 326.38% | HC Wainwright & Co. | $75 → $75 | Reiterates | Sell → Sell | |||
03/19/2025 | 462.82% | Deutsche Bank | $124 → $99 | Maintains | Hold |
FAQ
Quel est le cours indicatif de l'action Sarepta Therapeutics (SRPT) ?
Le dernier objectif de prix pour Sarepta Therapeutics (NASDAQ:SRPT) a été rapporté par Barclays le novembre 5, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $20.00 s'attendant à ce que SRPT se rise dans les 12 prochains mois (un possible changement de 13.70% upside). 100 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Sarepta Therapeutics (SRPT) ?
La dernière note d'analyste pour Sarepta Therapeutics (NASDAQ:SRPT) a été fournie par Barclays, et Sarepta Therapeutics maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Sarepta Therapeutics (SRPT) ?
La dernière amélioration pour Sarepta Therapeutics Inc a eu lieu le novembre 5, 2025 lorsque Mizuho a augmenté leur objectif de prix à $26. Mizuho avait précédemment a neutral pour Sarepta Therapeutics Inc.
Quand a eu lieu la dernière dégradation pour Sarepta Therapeutics (SRPT) ?
La dernière réduction pour Sarepta Therapeutics Inc a eu lieu le juillet 27, 2025 lorsque Barclays a changé leur objectif de prix de $18 à $10 pour Sarepta Therapeutics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Sarepta Therapeutics (SRPT) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Sarepta Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Sarepta Therapeutics a été déposée le novembre 5, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 5, 2026.
La note d'analyste pour Sarepta Therapeutics (SRPT) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Sarepta Therapeutics (SRPT) était un maintenu avec un objectif de prix de $22.00 à $20.00. Le prix actuel de Sarepta Therapeutics (SRPT) est de $17.59, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.